DECEMBER 11, 2019 – “Vivitrol is being promoted in a way that does not adequately present important risk information in a truthful and non-misleading manner,” Thomas Abrams, director of the FDA’s Office of Prescription Drug Promotion, said in a statement. “This is concerning from a public health perspective because of the potential for fatal opioid overdose in this vulnerable patient population.” … Some marketing campaigns for Vivitrol, a monthly injection that works to prevent opioid cravings and block opioids’ euphoric effects, have branded the drug as “non-addictive” in an attempt to distinguish it from two other addiction treatment drugs, methadone and buprenorphine, which are opioids themselves. Alkermes’ claims prompted an outcry from treatment advocates who see methadone and buprenorphine as valuable, more accessible, and potentially more effective tools to prevent opioid overdose.
GIVING BACK IN STYLE – April 17, 2024 - “It’s still one day at…
RIDING THE WAVE...CALMLY – April 18, 2024 - “I was 13 years old and…
VIDEO – NEW YORK STORIES – April 23, 2024 - Sara Gettelfinger had steadily…
TRY IT, YOU’LL LIKE IT – April 18, 2024 - The rise in “sober…
AUDIO – SOBER MEN CAN DO THAT – April 4, 2024 - Acting icon…
I’LL BET HE GOES TO GA (not Georgia) – April 13, 2024 -The initial…